SS-31 — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

SS-31

Also known as: Elamipretide, MTP-131, Bendavia, Szeto-Schiller-31, d-Arg-2,6-dimethyltyrosine-Lys-Phe-NH2, D-Arg-dimethylTyr-Lys-Phe-NH2

Mitochondria-targeted synthetic tetrapeptide antioxidant

Research chemicalLast updated: October 19, 2026Based on 48 peer-reviewed studies

What it is

SS-31 (elamipretide) is a synthetic peptide studied for protecting mitochondria — the energy generators in cells — from damage in diseases like heart failure, kidney injury, and rare mitochondrial disorders. It works by binding to a key mitochondrial membrane component and reducing oxidative damage. Not FDA-approved for commercial use; active Phase 2/3 trials ongoing.

The scientific side

SS-31 (elamipretide) is a synthetic tetrapeptide with alternating cationic and aromatic residues (d-Arg-2,6-dimethyltyrosine-Lys-Phe-NH2) that selectively targets and binds cardiolipin (CL), a phospholipid found in the inner mitochondrial membrane. This binding stabilizes mitochondrial cristae structure, reduces oxidative stress by scavenging reactive oxygen species (ROS), and enhances ATP production. SS-31 also maintains mitochondrial dynamics (fission/fusion balance), suppresses inflammatory signaling pathways (including NLRP3 inflammasome, NF-κB, and MAPK pathways), and prevents cellular apoptosis. A genome-wide CRISPR screen identified phospholipid scramblase 3 (PLSCR3), an inner mitochondrial membrane protein, as an essential biological target mediating SS-31's mitoprotective effects; SS-31 directly binds PLSCR3 and stimulates its scramblase activity. Additional mechanisms include promotion of mitophagy (via PHB2 and PINK1/Parkin pathways), modulation of macrophage polarization, upregulation of frataxin expression, and inhibition of alpha-synuclein membrane binding and aggregation.

Class: Mitochondria-targeted synthetic tetrapeptide antioxidant

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification. Abstract PMID 41966639 characterizes SS-31 among peptides operating in a 'gray market' of unapproved compounds marketed direct to patients, but does not…

WADA

Not stated in reviewed literature — requires manual verification.

Health Canada

Not stated in reviewed literature — requires manual verification.